Streetbeat News

Analyst Ratings

ABBV

A whale has taken a bearish stance on AbbVie (NYSE:ABBV), with 66% of detected unusual options trades being bearish. Whales have been targeting a price range of $80 to $160 for AbbVie over the last 3 months. Guggenheim, Wells Fargo, and Morgan Stanley maintain positive ratings on the stock.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 7:45 pm

VSAT

Needham has raised its price target on Viasat shares from $44 to $60, resulting in the stock trading higher.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 7:28 pm

ECX

Cantor Fitzgerald initiated coverage on ECARX Holdings with an Overweight rating and a $10 price target, causing the stock to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 7:27 pm

LUNA

Needham analyst Alex Henderson initiated coverage on Luna Innovations Inc (NASDAQ:LUNA) with a Buy rating and a $10 price target. Henderson cites LUNA's focus on fiber technology diagnostics, collaborations with Lockheed Martin, Airbus, and Intuitive Surgical, and growth in EV battery products as reasons for optimism.

Portfolio Pulse from Lekha Gupta

May 22, 2023 | 7:09 pm

IEP

Icahn Enterprises (IEP) shares are down 9.87% to $29.04, possibly due to continued volatility following a recent short seller report by Hindenburg. The report raises concerns about IEP's unsustainable 15.8% dividend yield and claims that IEP units are inflated by 75%+ due to three key reasons.

Portfolio Pulse from Henry Khederian

May 22, 2023 | 7:05 pm

TBI

BMO Capital Markets analyst Jeffrey M. Silber upgraded TrueBlue Inc (NYSE:TBI) to Outperform from Market Perform and increased the price target to $20 from $18. The upgrade follows recent industry data showing commercial staffing decline getting 'less worse' and better than the volume decline in professional staffing.

Portfolio Pulse from Lekha Gupta

May 22, 2023 | 7:04 pm

CYTK

In the last quarter, Cytokinetics (NASDAQ:CYTK) received 20 analyst ratings, with 10 bullish, 8 somewhat bullish, and 2 indifferent. The average 12-month price target for CYTK is $59.1, with a high of $71.00 and a low of $48.00. The average price target has increased by 0.92% over the past month.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 7:03 pm

CRUS

In the last quarter, Cirrus Logic (NASDAQ:CRUS) received 2 bullish, 3 somewhat bullish, and 1 indifferent analyst ratings. The company's average 12-month price target is $98.33, down 11.09% from the previous average of $110.60.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 7:02 pm

DVN

In the last quarter, Devon Energy (NYSE:DVN) received 9 bullish, 5 somewhat bullish, and 8 indifferent analyst ratings. The average 12-month price target for the company is $68.59, representing a 7.25% decrease from the previous average of $73.95.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 7:01 pm

PCG

In the last quarter, PG&E (NYSE:PCG) received 1 bullish, 2 somewhat bullish, and 4 indifferent analyst ratings. The average 12-month price target for the stock is $17.07, with a high of $20.50 and a low of $14.00. The average price target has increased by 10.84% over the past month.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 7:00 pm